Vigilent technologies: Securing health through scientific progress
Vigilent Technologies was founded in 2003 by senior research scientists (long-time CNRS* Research Directors active in Molecular Biology, Biochemistry, Genetics, Biophysics, Toxicology) and high profile, experienced engineers. Vigilent is located between Grenoble and Lyon, two major French research centres.
The company has three departments with specific, yet tightly interlinked aims.
three departments
Antiviral Therapies
Antiviral Therapies targeting viral diseases, namely those resisting vaccination (AIDS, Hepatitis etc...). Candidates are based on a patented "viral suicide" strategy.
Gene Optimization and Compilation
Providing full control over native protein synthesis, in view of:
- native proteins expression in heterologous systems and biotechnological applications thereof,
- early diagnosis and treatment of conformational diseases linked to protein misfolding (Alzheimer, Parkinson, diabetes type II etc...).
HT-Toxicogenomics
HT-Toxicogenomics for toxicity assessment of chemicals, with emphasis on reliability, low cost, high speed and high throughput. The HT-Toxicogenomics concept and the associated bioinformatics meet ideally the requirements of the E.U. REACH project, in particular for SMEs.
